DK0988863T4 - Stabile komplekser af tungtoplöselige forbindelser - Google Patents

Stabile komplekser af tungtoplöselige forbindelser

Info

Publication number
DK0988863T4
DK0988863T4 DK99117908T DK99117908T DK0988863T4 DK 0988863 T4 DK0988863 T4 DK 0988863T4 DK 99117908 T DK99117908 T DK 99117908T DK 99117908 T DK99117908 T DK 99117908T DK 0988863 T4 DK0988863 T4 DK 0988863T4
Authority
DK
Denmark
Prior art keywords
soluble compounds
stable complexes
heavily soluble
heavily
complexes
Prior art date
Application number
DK99117908T
Other languages
Danish (da)
English (en)
Other versions
DK0988863T3 (da
Inventor
Antonio A Albano
Wantanee Phuapradit
Harpreet K Sandhu
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0988863(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of DK0988863T3 publication Critical patent/DK0988863T3/da
Application granted granted Critical
Publication of DK0988863T4 publication Critical patent/DK0988863T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99117908T 1998-09-22 1999-09-13 Stabile komplekser af tungtoplöselige forbindelser DK0988863T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (2)

Publication Number Publication Date
DK0988863T3 DK0988863T3 (da) 2004-08-30
DK0988863T4 true DK0988863T4 (da) 2009-06-08

Family

ID=26798138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99117908T DK0988863T4 (da) 1998-09-22 1999-09-13 Stabile komplekser af tungtoplöselige forbindelser

Country Status (32)

Country Link
US (1) US6350786B1 (cs)
EP (1) EP0988863B2 (cs)
JP (5) JP2000095708A (cs)
KR (1) KR100362019B1 (cs)
CN (1) CN1201821C (cs)
AR (2) AR022096A1 (cs)
AT (1) ATE265232T1 (cs)
AU (1) AU770745B2 (cs)
BR (1) BR9904283A (cs)
CA (1) CA2282906C (cs)
CO (1) CO5140077A1 (cs)
CZ (1) CZ300215B6 (cs)
DE (1) DE69916733T3 (cs)
DK (1) DK0988863T4 (cs)
ES (1) ES2218918T5 (cs)
HR (1) HRP990287B1 (cs)
HU (1) HU228341B1 (cs)
ID (1) ID24034A (cs)
IL (1) IL131957A (cs)
MA (1) MA26692A1 (cs)
MY (1) MY124377A (cs)
NO (1) NO326928B1 (cs)
NZ (1) NZ337884A (cs)
PE (1) PE20001049A1 (cs)
PL (1) PL202757B1 (cs)
PT (1) PT988863E (cs)
RS (1) RS50193B (cs)
RU (1) RU2240827C2 (cs)
SG (1) SG97131A1 (cs)
SI (1) SI0988863T2 (cs)
TR (1) TR199902324A3 (cs)
TW (1) TWI234465B (cs)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
PE20010659A1 (es) * 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
ES2257407T3 (es) * 2000-05-16 2006-08-01 Ortho-Mcneil Pharmaceutical, Inc. Procedimiento para recubrir dispositivos medicos usando dioxido de carbono supercritico.
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6482847B2 (en) 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
WO2003013478A2 (en) * 2001-05-30 2003-02-20 Csir Method of encapsulating an active substance
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
EA200301250A1 (ru) 2001-06-22 2004-06-24 Пфайзер Продактс Инк. Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
RS61604A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
WO2004014342A1 (en) 2002-08-12 2004-02-19 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
EP3216449A1 (en) * 2003-11-14 2017-09-13 EA Pharma Co., Ltd. Oral administration preparation of phenylalanine derivatives
KR101118930B1 (ko) * 2003-11-14 2012-03-14 아지노모토 가부시키가이샤 페닐알라닌 유도체의 고체 분산체 또는 고체 분산체 의약제제
EP1735007A2 (en) * 2004-04-01 2006-12-27 F.Hoffmann-La Roche Ag Cyclodextrin inclusion complexes of pyrimidine-2,4,6-triones
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
CN101115469A (zh) * 2004-12-28 2008-01-30 卫材R&D管理有限公司 速崩片及其制造方法
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
WO2006081497A2 (en) * 2005-01-27 2006-08-03 Corium International, Inc. Hydrophilic biocompatible adhesive formulations and uses
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
CA2608952A1 (en) * 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
SI1893612T1 (sl) * 2005-06-22 2012-03-30 Plexxikon Inc Pirolo b piridin derivati kot protein kinazni inhibitorji
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
US20080221047A1 (en) * 2006-12-27 2008-09-11 Astellas Pharma Inc., Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20100222311A1 (en) * 2007-10-19 2010-09-02 Purdue Research Foundation Solid formulations of crystalline compounds
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
PL2414356T3 (pl) * 2009-04-03 2016-02-29 Hoffmann La Roche Kompozycje {3-[5-(4-chlorofenylo)-1H-pirolo[2,3-b]pirydyno-3-karbonylo]-2,4-difluorofenylo}-amidu kwasu propano-1-sulfonowego i ich zastosowania
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JPWO2011152297A1 (ja) * 2010-05-31 2013-08-01 アステラス製薬株式会社 トリアゾール化合物の固体分散体
ES2696023T3 (es) 2011-02-07 2019-01-11 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones para ello
MX2013008476A (es) 2011-02-17 2013-08-12 Hoffmann La Roche Proceso para cristalizacion controlada de un ingrediente farmaceutico activo a partir del estado liquido superenfriado por extrusion de fusion en caliente.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
HUE044043T2 (hu) 2011-06-20 2019-09-30 H Lundbeck As Deuterizált 1-piperazino-3-fenil-indánok skizofrénia kezelésére
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
IN2014CN02290A (cs) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
SG11201401459YA (en) 2011-10-14 2014-07-30 Array Biopharma Inc Solid dispersions of a erb2 (her2) inhibitor
PT2827900T (pt) 2012-03-23 2018-06-14 Array Biopharma Inc Dispersões sólidas amorfas para utilização no tratamento de cancro cerebral
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
AU2013346501B2 (en) 2012-11-19 2017-07-13 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of CETP inhibitors
CA2895534C (en) * 2012-12-20 2019-10-22 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
MX372668B (es) 2013-01-22 2020-04-23 Hoffmann La Roche Composicion farmaceutica que comprende un compuesto ácido 4-{[(2r, 3s, 4r, 5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico con biodisponibilidad mejorada.
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
US20160213575A1 (en) * 2013-09-11 2016-07-28 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
CA2928772A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
WO2016193779A1 (en) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
DK3447056T3 (da) * 2016-12-13 2025-06-30 Transthera Sciences Nanjing Inc Multikinasehæmmerforbindelse, krystalform og anvendelse deraf
BR112019022280A2 (pt) 2017-04-28 2020-05-19 Seattle Genetics Inc tratamento de cânceres de her2 positivo
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
CA3168667A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
AU2021212258A1 (en) 2020-01-31 2022-09-29 Flex Pharma, Llc Amorphous nilotinib microparticles and uses thereof
JP7705715B2 (ja) 2020-03-03 2025-07-10 デクセリアルズ株式会社 画像表示装置の製造方法
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
KR870004967A (ko) * 1985-11-27 1987-06-02 헤르비그 폰 모르체 무정형 벤즈 이미다졸 유도체
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
DE69628276T2 (de) * 1995-07-26 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Zubereitung von xanthinderivaten als feste dispersion
WO1997008950A1 (en) 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
NZ332234A (en) 1996-03-12 2000-06-23 Pg Txl Company Lp Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
EP0954288B1 (en) * 1996-06-28 2004-08-11 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
PT1064279E (pt) 1998-03-17 2003-10-31 Hoffmann La Roche Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular

Also Published As

Publication number Publication date
PL202757B1 (pl) 2009-07-31
JP2016196515A (ja) 2016-11-24
CN1201821C (zh) 2005-05-18
TWI234465B (en) 2005-06-21
SI0988863T1 (en) 2004-08-31
CA2282906A1 (en) 2000-03-22
JP6534979B2 (ja) 2019-06-26
DE69916733T3 (de) 2009-09-24
EP0988863B2 (en) 2009-03-18
US6350786B1 (en) 2002-02-26
MY124377A (en) 2006-06-30
NO326928B1 (no) 2009-03-16
MA26692A1 (fr) 2004-12-20
CZ300215B6 (cs) 2009-03-18
KR100362019B1 (ko) 2002-11-23
HU9903189D0 (en) 1999-11-29
AU770745B2 (en) 2004-03-04
JP6253135B2 (ja) 2017-12-27
EP0988863A3 (en) 2000-08-09
IL131957A (en) 2005-06-19
NZ337884A (en) 2001-02-23
PE20001049A1 (es) 2000-10-17
DE69916733D1 (de) 2004-06-03
CN1251312A (zh) 2000-04-26
BR9904283A (pt) 2000-09-26
ID24034A (id) 2000-07-06
HRP990287B1 (en) 2004-12-31
SG97131A1 (en) 2003-07-18
CO5140077A1 (es) 2002-03-22
EP0988863B1 (en) 2004-04-28
AR080892A2 (es) 2012-05-16
SI0988863T2 (sl) 2009-08-31
IL131957A0 (en) 2001-03-19
EP0988863A2 (en) 2000-03-29
PT988863E (pt) 2004-07-30
HUP9903189A3 (en) 2009-07-28
CZ330499A3 (cs) 2000-04-12
HRP990287A2 (en) 2000-06-30
CA2282906C (en) 2010-07-20
RU2240827C2 (ru) 2004-11-27
AU4880799A (en) 2000-03-23
JP2007224048A (ja) 2007-09-06
HK1026632A1 (en) 2000-12-22
AR022096A1 (es) 2002-09-04
PL335592A1 (en) 2000-03-27
DE69916733T2 (de) 2005-03-31
HU228341B1 (en) 2013-03-28
DK0988863T3 (da) 2004-08-30
JP2013035875A (ja) 2013-02-21
ES2218918T5 (es) 2009-06-23
ES2218918T3 (es) 2004-11-16
RS50193B (sr) 2009-05-06
TR199902324A2 (xx) 2000-04-21
YU47399A (cs) 2002-08-12
TR199902324A3 (tr) 2000-04-21
NO994583L (no) 2000-03-23
HUP9903189A2 (hu) 2000-06-28
NO994583D0 (no) 1999-09-21
KR20000023426A (ko) 2000-04-25
JP2000095708A (ja) 2000-04-04
ATE265232T1 (de) 2004-05-15
JP2015187170A (ja) 2015-10-29

Similar Documents

Publication Publication Date Title
DK0988863T4 (da) Stabile komplekser af tungtoplöselige forbindelser
DE60025198D1 (de) Stabile biozidale zusammensetzung
DE59902428D1 (de) Foggingfreies Klebeband
ATE311118T1 (de) Stabile salatsossen
DK1124961T3 (da) Trombopoietiske forbindelser
DK0900088T3 (da) Inklusionskomplekser af arylheterocykliske salte
DE69829864D1 (de) Stabile feste blockförmige waschmittelzusammensetzung
ATE248849T1 (de) Verbrückte metallkomplexe
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
NO20011745L (no) Forbindelser
IS5843A (is) Fenýl janþín (yanthine) afleiður
NO20005006L (no) Kalsilytiske forbindelser
IS5772A (is) Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum
DK1087992T3 (da) Antithrombotiske forbindelser
DE60007044D1 (de) Stabile biozide Zusammensetzungen
NO20006662D0 (no) Fluorfenylresin-forbindelser
DK1155050T3 (da) Fremstilling af polyolefin
DE59911099D1 (de) Stabile mitoxantron-lösungen
DE69903701D1 (de) Stabile 3-Isothiazolonzusammensetzungen
DE69910409D1 (de) Disaccharide-derivate
FI980902A7 (fi) Levosimendaanin stabiileja koostumuksia
DK1088010T3 (da) Fremstilling af polyolefiner
DE69813426D1 (de) Stabile Bleichmittelzusammensetzungen
ATE228522T1 (de) Dinukleare fluoroaryl-aluminium-alkylkomplexe